Tag: Martin Dyroff

Poster-Non-imaging Biomarkers

Concentration of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, in Cerebrospinal Fluid during Treatment of Patients with Relapsing Multiple Sclerosis in a Phase 2 Study

Background: Evobrutinib, a highly selective Bruton’s tyrosine kinase (BTK) inhibitor, demonstrated a low annualized relapse rate (75mg...

Read More